SNY
Sanofi·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
High Gross Profit Margin
Gap Down
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNY
Sanofi
One of the world's largest vaccines producer
Pharmaceutical
--
01/02/2019
NASDAQ Stock Exchange
82,878
12-31
Depository Receipts (Ordinary Shares)
46, avenue de la Grande Armee, 75017 Paris, France
Research, development and production of pharmaceutical and vaccine products
Sanofi was incorporated in 1994 under the laws of France. The company is a leading global healthcare company focused on patient needs and engaged in the research, development, manufacturing and marketing of therapeutic solutions. The company's activities are organized around the following categories: DUPIXENT, Neurology & Immunology, Rare Diseases, Oncology, Rare Hematological Diseases, Generic Core Assets and Non-Core Assets, Vaccines, CHC.
Earnings Call
Q1/2025
Estimate EPS0.95
Actual EPS1.640992
Estimate Revenue11.10B
Actual Revenue11.45B
Innate Pharma's Q1 2025: Navigating Contradictions in Lacutamab Development and Strategic Partnerships
May 20,2025 12:07
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1
Actual EPS3.81348
Estimate Revenue11.46B
Actual Revenue12.64B
Novavax's 2025 Q2 Earnings Call: Navigating Key Contradictions in CIC Strategy and Regulatory Pathways
Aug 13,2025 01:45
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SNY has released its 2023 Q4 earnings. EPS was reported at 0.89, versus the expected 1.5, missing expectations. The chart below visualizes how SNY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SNY has released its 2025 Q3 earnings report, with revenue of 15.45B, reflecting a YoY change of 6.86%, and net profit of 3.30B, showing a YoY change of 3.96%. The Sankey diagram below clearly presents SNY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
